RICHMOND, British Columbia, Jan. 10, 2008 (PRIME NEWSWIRE) -- The licensing agreement for BioCurex’s (OTCBB:BOCX) RECAF material and technology, just signed with Inverness Medical Innovations Inc., moves BioCurex closer to the commercialization of its cancer detection products. This is an important step forward in the company’s development, and follows a similar agreement with Abbott Laboratories.
